| Literature DB >> 35055206 |
Adelina-Gabriela Niculescu1, Alexandru Mihai Grumezescu1,2,3.
Abstract
Chitosan and alginate are two of the most studied natural polymers that have attracted interest for multiple uses in their nano form. The biomedical field is one of the domains benefiting the most from the development of nanotechnology, as increasing research interest has been oriented to developing chitosan-alginate biocompatible delivery vehicles, antimicrobial agents, and vaccine adjuvants. Moreover, these nanomaterials of natural origin have also become appealing for environmental protection (e.g., water treatment, environmental-friendly fertilizers, herbicides, and pesticides) and the food industry. In this respect, the present paper aims to discuss some of the newest applications of chitosan-alginate-based nanomaterials and serve as an inception point for further research in the field.Entities:
Keywords: alginate; biomedical applications; chitosan; chitosan-alginate nanoparticles; drug delivery systems; polysaccharide nanoparticles
Year: 2022 PMID: 35055206 PMCID: PMC8778629 DOI: 10.3390/nano12020186
Source DB: PubMed Journal: Nanomaterials (Basel) ISSN: 2079-4991 Impact factor: 5.076
Figure 1Chemical structures of chitosan and alginate. Chitosan has a linear structure comprised of β–(1-4) linked 2-acetamide-2-deoxy-d-glucose and 2-amino-2-deoxy-d-glucose [49], while alginate is a copolymer of β-D-mannuronic acid (M) and α-L-guluronic acid (G) which, in the presence of calcium ions form an egg-box structure [50]. Adapted from open-access sources.
Figure 2Schematic representation of nanoparticles production via IG method. Reprinted with permission from [64], © 2020, Society of Chemical Industry, Published by John Wiley and Sons.
Figure 3Administration routes for chitosan-alginate-based drug delivery systems.
Figure 4Schematic representation of the delivery system developed by Maity et al. [69]. Reprinted with permission from [69]. © 2017, Elsevier Ltd.
Examples of oral drug delivery systems based on chitosan-alginate nanoparticles.
| Delivery System | Carried Drug | Synthesis Method | Physicochemical Properties | Applications | Ref. |
|---|---|---|---|---|---|
| CANPs | Curcumin diethyl diglutarate | Oil in water emulsification & ionotropic gelation | Size: 215 nm | Cancer treatment | [ |
| CANPs | Curcumin diglutaric acid | Oil in water emulsification & ionotropic gelation | Size: 212–552 nm | Cancer treatment | [ |
| Succinylated chitosan-alginate core-shell-corona NPs | Quercetin | Ionic cross-linking | Minimum size: ~91.58 nm | Diabetes treatment | [ |
| Chitosan-coated alginate NPs | Insulin | Polyelectrolyte complexation & ionotropic gelation | Size: 340.40 ± 2.39 nm | Diabetes treatment | [ |
| Polyelectrolyte complexes of chitosan-coated NPs and alginate-coated NPs | Insulin | Optimized double emulsion method | Composition: ( | Diabetes treatment | [ |
| Alginate coated chitosan core-shell NPs | Naringenin | Sonication | Size: 216.44 ± 6 nm | Diabetes treatment | [ |
| CANPs | Lovastatin | Ionic gelation | Shape: spherical | Treatment of obesity and cardiovascular disease | [ |
| CANPs | Rosuvastatin calcium | Ionotropic pre-gelation & polyelectrolyte complexation | Size: ~349.3 nm | Antilipidemic formulation | [ |
| CANPs | Quercetin | Electrostatic gelation | Two types of nanoparticles: | Protection against oxidative stress | [ |
| CANPs | Quercetin | Electrostatic gelation | Two types of nanoparticles: | Therapeutic approach against oxidative stress-induced liver injury | [ |
| Chitosan-alginate core-shell corona shaped NPs | Dimethyl fumarate | Ionotropic pre-gelation & polyelectrolyte complexation | Size: 561 ± 53.05 nm | Multiple sclerosis treatment | [ |
| Chitosan oligosaccharide/alginate NPs | Astaxanthin | Oil in water emulsification & ionotropic gelation | Size: 264 ± 32 nm | Nutraceutical or functional foods | [ |
Examples of ocular drug delivery systems based on chitosan-alginate nanoparticles.
| Delivery System | Carried Drug | Synthesis Method | Physicochemical Properties | Applications | Ref. |
|---|---|---|---|---|---|
| Chitosan-coated alginate NPs | Daptomycin | Ionotropic pre-gelation & polyelectrolyte complexation | Size: 380–420 nm | Treatment of bacterial endophthalmitis | [ |
| Chitosan-coated CANPs | 5-Fluorouracil | Ionic gelation | Size: 329–505 nm | Conjunctival/ | [ |
| Chitosan-oleic acid-sodium alginate NPs | Lutein | Ionic gelation | Size: 40–160 nm | Therapeutic approach against macular degeneration and diabetic retinopathy | [ |
| Chitosan-alginate microspheres | Azelastine hydrochloride | Modified ionic gelation | Size: 3.55–6.70 μm | Conjunctivitis treatment | [ |
| CANPs | Ofloxacin | Modified ionotropic gelation | Size: 113.8–509 nm | Eye infections | [ |
| Chitosan-coated alginate NPs | Betamethasone sodium phosphate | Electrospraying & emulsification | Size: 150–300 nm | Eye diseases | [ |
| Thiolated chitosan and sodium alginate NPs | Fluorescein isothiocyanate | Modified ionic gelation | Size: 408.0 ± 6.4 nm | Eye diseases | [ |
Figure 5Schematic representation of the synthesis mechanism and final structure of the delivery system developed by Sahatsapan et al. [106]. Reprinted with permission from [106], © 2021, Elsevier B.V.
Examples of chitosan-alginate nanoparticles for various administration routes.
| Delivery System | Carried Drug | Synthesis Method | Physicochemical Properties | Administration Route | Applications | Ref. |
|---|---|---|---|---|---|---|
| CANPs | Bee venom | Oil in water emulsification | Size: 434.6 ± 22.1 nm | Nasal | PRRSV | [ |
| CANPs | Rifampicin | Ionic gelation | Size: 300 ± 30 nm | Intratracheal | [ | |
| CANPs | Doxorubicin | Electrostatic gelation | Shape: spherical | Intravenous | Melanoma treatment | [ |
| Chitosan-alginate-sodium tripolyphosphate (STPP) NPs | Curcumin | Sonication | Shape: spherical | Intravenous | Epilepsy treatment | [ |
| CANPs | Pirfenidone | Pre-gelation | Shape: spherical | Transdermal | Treatment of idiopathic pulmonary fibrosis | [ |
| Mal-CS-Cat-Alg NPs | Doxorubicin | Ionic gelation & sonication | Shape: spherical | Intravesical | Bladder cancer treatment | [ |
| Chitosan-coated alginate microcapsules | Probiotics | Extrusion of polymer dispersions & polyelectrolyte complexations | Shape: spherical | Periodontal | Periodontal disease | [ |
Examples of in vitro-tested drug delivery systems based on chitosan-alginate nanoparticles.
| Delivery System | Carried Drug | Synthesis Method | Physicochemical Properties | Applications | Ref. |
|---|---|---|---|---|---|
| CANPs | Endolysin | Ionotropic pre-gelation & polyelectrolyte complexation | Hydrodynamic diameter: 276.5 ± 42 nm | Staphylococcal infections | [ |
| CANPs stabilized with carrageenan | Ethionamide | Ionotropic gelation | Shape: spherical | Tuberculosis treatment | [ |
| CANPs | Curcumin | Oil in water emulsification & ionotropic gelation | Size: ~400 nm | Photodynamic therapy system for psoriasis treatment | [ |
| CANPS | Crocin | Ultrasonic-mediated synthesis | Size: 236 nm | Cancer treatment | [ |
| Chitosan-alginate-STPP NPs | Curcumin | Ultrasonic-assisted synthesis | Shape: spherical | Cancer treatment | [ |
| CANPs | Doxorubicin | Ionotropic gelation | Size: ~300 nm | Lymphoma treatment | [ |
| Alginate-coated chitosan hollow nanospheres | Doxorubicin | Hard template method | Diameter: ~150 nm | Lung cancer treatment | [ |
| CANPs | Quercetin | Ionotropic gelation & ultrasonication | Shape: rod-like | Pharmaceutical applications | [ |
Figure 6Overview of chitosan-alginate-based anticancer nanoformulations.
Figure 7Overview of chitosan-alginate-based antimicrobial nanoformulations.
Figure 8Schematic representation of the vaccine delivery systems developed by Zhao et al. [139]. Reprinted from an open-access source.
Figure 9Schematic representation of synthesis mechanism and final structure of chitosan-alginate-based nanocomposite developed by Ahmed et al. [143]. Reprinted from an open-access source.
Figure 10Examples of chitosan-alginate-based nanomaterials applications in agriculture.